Evidence map›Paper›PMID 39031388›Full record

ReviewJournal of Parkinson's disease2024

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.

Kevin McFarthing, Sue Buff, Gary Rafaloff, Kenneth Pitzer, Brian Fiske, Anaya Navangul, Katelyn Beissert, Aleksandra Pilcicka, Rosie Fuest, Richard K Wyse and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Towards the Prevention of Freezing of Gait in Parkinson's Disease.The European journal of neuroscience · 2026
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Observational

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kevin McFarthingParkinson's Research Advocate, Oxford, UK.
Sue BuffParkinson's Research Advocate, Sunnyvale, CA, USA.
Gary RafaloffParkinson's Research Advocate, Westlake, FL, USA.
Kenneth PitzerParkinson's Research Advocate, Pacific Grove, CA, USA.
Brian FiskeThe Michael J Fox Foundation for Parkinson's Research, New York, USA.
Anaya NavangulCure Parkinson's, London, UK.
Katelyn BeissertCure Parkinson's, London, UK.
Aleksandra PilcickaCure Parkinson's, London, UK.
Rosie FuestCure Parkinson's, London, UK.
Richard K WyseCure Parkinson's, London, UK.
Simon R W StottCure Parkinson's, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: For the past five years, our annual reports have been tracking the clinical development of new drug-based therapies for the neurodegenerative condition of Parkinson's disease (PD). These reviews have followed the progress both of "symptomatic treatments" (ST - improves/reduces symptoms of the condition) and "disease-modifying treatments" (DMT - attempts to delay/slow progression by addressing the underlying biology of PD). Efforts have also been made to further categorize these experimental treatments based on their mechanisms of action and class of drug. Methods: A dataset of clinical trials for drug therapies in PD using trial data downloaded from the ClinicalTrials.gov online registry was generated. A breakdown analysis of all the studies that were active as of January 31st, 2024, was conducted. This analysis involved categorizing the trials based on both the mechanism of action (MOA) and the drug target. Results: There were 136 active Phase 1-3 trials evaluating drug therapies for PD registered on ClinicalTrials.gov, as of January 31, 2024. Of these trials, 76 (56%) were classified as ST trials and 60 (44%) were designated DMT. More than half (58%) of the trials were in Phase 2 testing stage, followed by Phase 1 (30%) and Phase 3 (12%). 35 of the trials were registered since our last report, with the remaining 101 trials appearing in at least one earlier report. Conclusions: The drug development pipeline for PD remains in a robust state with a wide variety of approaches being developed and evaluated in Phase 1 and 2. Yet again, however, only a limited number of DMTs are transitioning to Phase 3.

Indexed as

Antiparkinson AgentsClinical Trials as TopicParkinson DiseaseHumansAntiparkinson AgentsClinical trialsdisease modificationgene therapyimmunotherapyinflammationneuroprotectionParkinson’sstudies

Identifiers

PMID39031388
PMCPMC11307066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.